Verona Pharma plc
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Verona Pharma plc
RECRUITINGPhase 2NCT05270525
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods....
Sponsor: Verona Pharma plcEnrolling: 563 locations
COPD
RECRUITINGPhase 2NCT06559150
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily...
Sponsor: Verona Pharma plcEnrolling: 18020 locations
Non-cystic Fibrosis Bronchiectasis